GZMB and melanoma: Furthermore, LXR-mediated MDSC depletion with an LXR agonist was associated with a significant increase in IFN-γ and granzyme B positive TILs in vivo in mouse melanoma models, which enhanced the anti-tumour activity of anti-PD-1 therapy and significantly impaired tumour growth.